Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

Sodium –glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a...

Source: Cardiovascular Diabetology - January 7, 2021 Category: Cardiology Authors: David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing, Alessio Alogna, Daniel Messroghli, Burkert M. Pieske, Frank R. Heinzel and Felix Hohendanner Tags: Original investigation Source Type: research